Edition:
United States

MediciNova Inc (4875.T)

4875.T on Tokyo Stock Exchange

761JPY
14 Dec 2017
Change (% chg)

¥18 (+2.42%)
Prev Close
¥743
Open
¥745
Day's High
¥762
Day's Low
¥745
Volume
119,100
Avg. Vol
228,959
52-wk High
¥923
52-wk Low
¥480

Chart for

About

Medicinova, Inc. is a biopharmaceutical company. The Company focuses on acquiring and developing small molecule therapeutics for the treatment of diseases with unmet medical needs and a commercial focus on the United States market. Its pipeline includes MN-166 (ibudilast), MN-001 (tipelukast), MN-221 (bedoradrine) and MN-029... (more)

Overall

Beta: 0.38
Market Cap(Mil.): ¥26,411.07
Shares Outstanding(Mil.): 36.10
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 198.20 16.04
EPS (TTM): -- -- --
ROI: -- -11.76 34.69
ROE: -- -36.72 15.46

BRIEF-Medicinova Announces Positive Top-Line Results From Clinical Trial Of MN-166 (ibudilast) In ALS

* MEDICINOVA ANNOUNCES POSITIVE TOP-LINE RESULTS FROM THE CLINICAL TRIAL OF MN-166 (IBUDILAST) IN ALS

Dec 07 2017

BRIEF-Medicinova announces collaboration

* Medicinova announces collaboration with the U.S. Department Of Veterans Affairs and Oregon Health & Science University to evaluate MN-166 (ibudilast) in methamphetamine use disorder

Nov 09 2017

BRIEF-Medicinova announces positive top-line results from the Sprint-MS Phase 2B trial of MN-166 (ibudilast)

* Medicinova announces positive top-line results from the Sprint-MS phase 2B trial of MN-166 (ibudilast) in progressive MS: achieved both primary endpoints including a significant reduction in whole brain atrophy and safety and tolerability

Oct 26 2017

BRIEF-Medicinova Inc files for potential mixed ‍​shelf of up to $200 million

* Medicinova Inc files for potential mixed ‍​shelf of up to $200 million - SEC filing Source text: [http://bit.ly/2fgDO2R] Further company coverage:

Sep 22 2017

BRIEF-MediciNova completes enrollment in the phase 2 trial of MN-166 in methamphetamine dependence

* MediciNova announces the completion of enrollment in the phase 2 clinical trial of MN-166 (ibudilast) in methamphetamine dependence

Sep 19 2017

Earnings vs. Estimates